Vinorelbine
Information
- Drug Name
- Vinorelbine
- Description
- Entry(CIViC)
- 5
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung non-small cell carcinoma |
RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 24647522 | Detail |
| lung non-small cell carcinoma |
RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
Unknown
|
3 | 23038758 | Detail |
| lung non-small cell carcinoma |
XRCC1 p.Arg194Trp (p.R194W) ( ENST00000262887.10, ENST00000543982.5 ) XRCC1 p.Arg194Trp (p.R194W) ( ENST00000262887.10, ENST00000543982.5 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 4 | 19157633 | Detail |
| lung non-small cell carcinoma | SMARCA4 UNDEREXPRESSION SMARCA4 UNDEREXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 26671993 | Detail |
| malignant mesothelioma | BRCA1 EXPRESSION BRCA1 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 22190288 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In this study, 229 tumors were analyzed for RRM1 e... | RRM1 |
RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The study began with a total of 443 patients that ... | RRM1 |
RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The XRCC1 R194W variant was shown to be correlated... | XRCC1 |
XRCC1 p.Arg194Trp (p.R194W) ( ENST00000262887.10, ENST00000543982.5 ) XRCC1 p.Arg194Trp (p.R194W) ( ENST00000262887.10, ENST00000543982.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| SMARCA4 expression was determined with gene expres... | SMARCA4 | SMARCA4 UNDEREXPRESSION SMARCA4 UNDEREXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| Expression of BRCA1 in 6 mesothelioma cell lines w... | BRCA1 | BRCA1 EXPRESSION BRCA1 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03456076 | Active, not recruiting | Phase 3 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | August 16, 2018 | November 19, 2026 |
| NCT00431704 | Active, not recruiting | Phase 2 | VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer | October 2007 | December 2023 |
| NCT05104866 | Active, not recruiting | Phase 3 | A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | October 18, 2021 | August 15, 2025 |
| NCT05063786 | Active, not recruiting | Phase 3 | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | September 14, 2021 | November 2024 |
| NCT02998528 | Active, not recruiting | Phase 3 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | March 4, 2017 | November 8, 2028 |
| NCT03620032 | Active, not recruiting | Phase 2 | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses | November 2, 2015 | November 2, 2024 |
| NCT04697628 | Active, not recruiting | Phase 3 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | February 22, 2021 | August 5, 2025 |
| NCT04145349 | Active, not recruiting | Phase 1/Phase 2 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | January 22, 2020 | October 31, 2024 |
| NCT02486718 | Active, not recruiting | Phase 3 | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] | October 31, 2015 | August 30, 2035 |
| NCT02567435 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | June 1, 2016 | October 1, 2024 |
| NCT02892123 | Active, not recruiting | Phase 1 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | September 30, 2016 | July 1, 2024 |
| NCT03442673 | Active, not recruiting | Phase 2 | Chemotherapy and G-CSF for Mobilization | September 17, 2018 | May 2024 |
| NCT02344472 | Active, not recruiting | Phase 3 | Detect V / CHEVENDO (Chemo vs. Endo) | September 2015 | January 31, 2025 |
| NCT03414658 | Active, not recruiting | Phase 2 | The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | June 21, 2018 | May 31, 2025 |
| NCT02465736 | Active, not recruiting | Phase 3 | Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308) | July 2015 | July 2025 |
| NCT00193921 | Completed | Phase 2 | Chemoradiotherapy in Patients With Localised Lung Cancer | February 2003 | December 2012 |
| NCT00194727 | Completed | Phase 2 | Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer | May 2002 | March 2011 |
| NCT00194740 | Completed | Phase 2 | Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer | November 1997 | June 2007 |
| NCT00215462 | Completed | Phase 2 | Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma | June 2000 | August 2005 |
| NCT00215930 | Completed | Phase 2 | The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer | February 2004 | October 2009 |
| NCT03801304 | Completed | Phase 2 | Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer | January 24, 2019 | February 23, 2022 |
| NCT00256282 | Completed | Phase 2 | Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma | April 2003 | August 2012 |
| NCT00256711 | Completed | Phase 2 | Phase II Iressa Versus Vinorelbine (INVITE) | July 2004 | February 2006 |
| NCT00277069 | Completed | Phase 1/Phase 2 | Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer | May 2000 | March 2006 |
| NCT00280878 | Completed | Phase 2 | Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma | January 2006 | September 2007 |
| NCT00295672 | Completed | Phase 2 | Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC. | February 2006 | June 2007 |
| NCT00325234 | Completed | Phase 2 | Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer | June 2006 | August 2010 |
| NCT00333294 | Completed | Phase 2 | Phase II Iressa + Irradiation Followed by Chemo in NSCLC | September 2004 | January 2006 |
| NCT00349089 | Completed | Phase 2 | Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy | September 26, 2006 | April 14, 2014 |
| NCT00388349 | Completed | Phase 2 | Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | September 2001 | September 2010 |
| NCT00401427 | Completed | Phase 2 | HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer | November 2002 | December 2006 |
| NCT00401492 | Completed | Phase 2 | MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer | June 2002 | April 2007 |
| NCT00401609 | Completed | Phase 1/Phase 2 | G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients | November 2000 | February 2009 |
| NCT00431106 | Completed | Phase 3 | Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer | April 2002 | January 2009 |
| NCT00441740 | Completed | Phase 3 | Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer | April 2004 | February 2008 |
| NCT00441922 | Completed | Phase 3 | Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) | January 2003 | January 2008 |
| NCT03397953 | Completed | Phase 2 | Vinorelbine for Recurrent ACLC | November 2016 | July 2022 |
| NCT03345810 | Completed | Phase 2 | Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) | December 14, 2017 | December 31, 2022 |
| NCT00477035 | Completed | Phase 1 | Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | May 2006 | March 2011 |
| NCT00480597 | Completed | Phase 2 | Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer | October 2002 | |
| NCT00499109 | Completed | Phase 3 | Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC | May 2007 | November 2013 |
| NCT00503750 | Completed | Phase 2 | Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™) | April 2008 | July 2011 |
| NCT00513058 | Completed | Phase 1 | Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer | June 2007 | April 2012 |
| NCT03321981 | Completed | Phase 2 | MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. | January 15, 2018 | July 26, 2023 |
| NCT00620971 | Completed | Phase 2 | Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC | January 2008 | April 2010 |
| NCT00670982 | Completed | Phase 2 | Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer | May 2008 | December 2012 |
| NCT00686959 | Completed | Phase 3 | Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer | September 2008 | November 2014 |
| NCT03254654 | Completed | Phase 2 | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer | August 16, 2017 | August 1, 2021 |
| NCT03191786 | Completed | Phase 3 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy | September 11, 2017 | October 25, 2023 |
| NCT00706030 | Completed | Phase 1/Phase 2 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | April 29, 2008 | June 7, 2018 |
| NCT00724386 | Completed | Phase 1 | Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer | June 1999 | November 2012 |
| NCT00737867 | Completed | Phase 3 | Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer | September 2007 | February 2011 |
| NCT03161054 | Completed | Phase 2 | Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas | September 12, 2017 | June 21, 2021 |
| NCT00755170 | Completed | Phase 2 | Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer | November 2008 | October 2016 |
| NCT00773188 | Completed | Phase 1 | A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer. | December 2008 | October 2010 |
| NCT00842595 | Completed | Phase 2 | Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas | December 2003 | May 2010 |
| NCT00842712 | Completed | Phase 2 | Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) | February 2009 | July 2013 |
| NCT00868634 | Completed | Phase 3 | Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer | February 2009 | October 2015 |
| NCT00958724 | Completed | Phase 1 | Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors | July 2009 | April 2010 |
| NCT01007942 | Completed | Phase 3 | Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer | October 2009 | June 2015 |
| NCT01013740 | Completed | Phase 2 | Lapatinib in Combination With Vinorelbine | November 25, 2009 | March 1, 2016 |
| NCT03007992 | Completed | Phase 2 | Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer | December 2016 | March 2, 2019 |
| NCT01029678 | Completed | Phase 2 | Concomitant Radio-chemotherapy in the Elderly | January 2010 | June 2016 |
| NCT02991482 | Completed | Phase 3 | PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma | September 12, 2017 | November 30, 2021 |
| NCT01109524 | Completed | Phase 2 | Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer | July 2010 | September 2012 |
| NCT01125566 | Completed | Phase 3 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | June 22, 2010 | July 6, 2018 |
| NCT02954055 | Completed | Phase 2 | MEtronomic TrEatment Option in Advanced bReast cAncer | September 13, 2017 | November 23, 2022 |
| NCT01196078 | Completed | Phase 4 | A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer | February 2007 | December 2010 |
| NCT01209520 | Completed | N/A | Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy | July 2009 | |
| NCT01242449 | Completed | Phase 2 | Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer | November 2010 | October 2014 |
| NCT02915744 | Completed | Phase 3 | A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | November 2016 | July 2020 |
| NCT01305941 | Completed | Phase 2 | A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases | September 2011 | October 16, 2017 |
| NCT01439191 | Completed | Phase 2 | Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer | July 2005 | May 2007 |
| NCT01441596 | Completed | Phase 2 | Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases | October 2011 | August 2014 |
| NCT01497860 | Completed | Phase 2 | Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas | July 2011 | July 2017 |
| NCT01520103 | Completed | Phase 2 | Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer | January 2012 | October 31, 2016 |
| NCT01565083 | Completed | Phase 2 | A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer | April 2012 | October 2015 |
| NCT01683682 | Completed | Phase 1 | An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2) | April 2013 | |
| NCT01684111 | Completed | Phase 1 | An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1) | June 2013 | |
| NCT01687439 | Completed | Phase 2 | Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC) | December 2008 | October 2009 |
| NCT02791373 | Completed | Phase 2 | Vinorelbine and Gemcitabine in Myeloma | March 2014 | December 31, 2017 |
| NCT01835236 | Completed | Phase 2 | Trastuzumab & Pertuzumab Followed by T-DM1 in MBC | March 3, 2013 | May 26, 2020 |
| NCT01848613 | Completed | Phase 4 | Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC | October 2012 | May 2018 |
| NCT02709720 | Completed | Phase 2 | Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC | April 15, 2016 | December 16, 2019 |
| NCT02610140 | Completed | Phase 2 | Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) | December 3, 2015 | September 6, 2019 |
| NCT02139904 | Completed | Phase 2 | Vinorelbine in Mesothelioma | March 1, 2016 | March 17, 2021 |
| NCT02574455 | Completed | Phase 3 | Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) | November 7, 2017 | December 8, 2020 |
| NCT02176369 | Completed | Phase 2 | Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial | February 2013 | October 27, 2018 |
| NCT02555657 | Completed | Phase 3 | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | October 13, 2015 | November 10, 2020 |
| NCT02555007 | Completed | Phase 1 | Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM | August 26, 2015 | October 25, 2022 |
| NCT02352948 | Completed | Phase 3 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | January 13, 2015 | August 30, 2023 |
| NCT02489903 | Completed | Phase 2 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | June 2015 | December 6, 2021 |
| NCT00003587 | Completed | Phase 2 | S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | October 1998 | January 2007 |
| NCT00003828 | Completed | Phase 2 | S9804: Vinorelbine in Treating Patients With Stage IV Melanoma | May 1999 | March 2004 |
| NCT00001944 | Completed | Phase 1 | Vinorelbine and XR9576 to Treat Cancer | December 1999 | June 2001 |
| NCT00015938 | Completed | Phase 2 | S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer | May 2001 | November 2012 |
| NCT00041067 | Completed | Phase 2 | S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer | September 2002 | January 2012 |
| NCT00128310 | Completed | Phase 3 | Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients | January 18, 2001 | January 24, 2008 |
| NCT00134641 | Completed | Phase 2 | Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas | February 2003 | June 2007 |
| NCT04903652 | Completed | Phase 2 | Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer | January 1, 2021 | February 6, 2022 |
| NCT00146549 | Completed | Phase 3 | Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer | August 2001 | December 2007 |
| NCT00151086 | Completed | Phase 1/Phase 2 | Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer | December 2001 | August 2006 |
| NCT03901339 | Completed | Phase 3 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | May 8, 2019 | October 20, 2023 |
| NCT00192062 | Completed | Phase 2 | A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer | July 2004 | June 2007 |
| NCT00193089 | Completed | Phase 2 | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer | April 2001 | September 2009 |
| NCT00193362 | Completed | Phase 3 | Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer | June 2004 | September 2007 |
| NCT02497118 | Completed | Phase 4 | Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC | August 2010 | June 2015 |
| NCT02985658 | No longer available | Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | |||
| NCT06459180 | Not yet recruiting | Phase 3 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | July 5, 2024 | October 23, 2028 |
| NCT04143906 | Not yet recruiting | Phase 2 | Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer | October 25, 2019 | December 31, 2024 |
| NCT04963595 | Not yet recruiting | Phase 2 | Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer | August 1, 2021 | July 31, 2024 |
| NCT05603013 | Not yet recruiting | Phase 2 | Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0) | October 30, 2022 | October 17, 2024 |
| NCT06081959 | Not yet recruiting | Phase 3 | A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | November 30, 2023 | December 31, 2027 |
| NCT06229067 | Not yet recruiting | Phase 2 | Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | January 19, 2024 | January 19, 2027 |
| NCT06382142 | Not yet recruiting | Phase 3 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer | May 2024 | May 2026 |
| NCT06435429 | Not yet recruiting | Phase 3 | A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | July 16, 2024 | April 25, 2031 |
| NCT06343948 | Recruiting | Phase 3 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer | April 24, 2024 | May 2026 |
| NCT04625907 | Recruiting | Phase 1/Phase 2 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma | September 17, 2020 | June 2030 |
| NCT06102824 | Recruiting | Phase 2 | Organoid-based Functional Precision Therapy for Advanced Breast Cancer | January 20, 2024 | June 30, 2028 |
| NCT03270007 | Recruiting | Phase 4 | Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy | November 10, 2017 | December 31, 2024 |
| NCT06023641 | Recruiting | Phase 1/Phase 2 | Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | March 13, 2024 | October 2037 |
| NCT05583110 | Recruiting | Phase 2 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer | March 8, 2023 | August 2026 |
| NCT06377566 | Recruiting | Phase 2 | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | April 17, 2024 | April 2027 |
| NCT03393741 | Recruiting | Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy | January 29, 2018 | August 2024 | |
| NCT05999994 | Recruiting | Phase 2 | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | January 22, 2020 | May 1, 2026 |
| NCT04388839 | Recruiting | Phase 2 | Evolutionary Therapy for Rhabdomyosarcoma | September 27, 2020 | December 2027 |
| NCT04304352 | Recruiting | Phase 2 | Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients | July 29, 2011 | December 31, 2023 |
| NCT04299113 | Recruiting | Phase 1 | Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma | May 14, 2020 | May 22, 2026 |
| NCT06268652 | Recruiting | Phase 3 | Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | January 15, 2024 | January 15, 2028 |
| NCT03443128 | Recruiting | Phase 2 | Vinorelbine for Recurrent ALCL-2017 | November 2016 | September 2025 |
| NCT05764941 | Recruiting | Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer | January 1, 2020 | March 31, 2024 | |
| NCT03618550 | Recruiting | Phase 2 | Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | August 1, 2018 | August 2024 |
| NCT04681911 | Recruiting | Phase 2 | Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | September 9, 2020 | September 9, 2024 |
| NCT00130507 | Terminated | Phase 2 | Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab | November 4, 2005 | July 25, 2009 |
| NCT02658084 | Terminated | Phase 1/Phase 2 | Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer | April 12, 2017 | October 11, 2018 |
| NCT02730091 | Terminated | Phase 3 | A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease | February 24, 2016 | March 23, 2020 |
| NCT01254136 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer | October 2010 | October 2011 |
| NCT01185509 | Terminated | Phase 2 | Trastuzumab and Vinorelbine in Advanced Breast Cancer | November 2010 | January 2018 |
| NCT01060514 | Terminated | Phase 1 | Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer | February 2010 | September 2013 |
| NCT01038037 | Terminated | Phase 2 | First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer | January 2010 | December 2013 |
| NCT00754702 | Terminated | Phase 2 | Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer | October 2008 | March 2011 |
| NCT00705549 | Terminated | Phase 2 | Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | February 2008 | September 2011 |
| NCT00694200 | Terminated | Phase 2 | Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer | April 2008 | December 2009 |
| NCT00597116 | Terminated | Phase 2 | An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma | December 2007 | January 2010 |
| NCT00455572 | Terminated | Phase 1 | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer | May 11, 2007 | August 8, 2013 |
| NCT03386721 | Terminated | Phase 2 | Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors | February 19, 2018 | December 30, 2021 |
| NCT00453635 | Terminated | Phase 2 | Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients | December 2003 | November 2008 |
| NCT00403988 | Terminated | Phase 2 | Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma | June 2004 | December 2007 |
| NCT00345059 | Terminated | Phase 3 | The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | May 2005 | May 2008 |
| NCT00235235 | Terminated | A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer | September 2005 | December 2010 | |
| NCT00225173 | Terminated | Phase 2 | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | October 2001 | September 2006 |
| NCT03891173 | Terminated | Phase 2 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | February 19, 2019 | May 22, 2020 |
| NCT00176488 | Terminated | Phase 2 | Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | June 2003 | October 2009 |
| NCT00004093 | Terminated | Phase 1/Phase 2 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | August 1999 | March 2002 |
| NCT00169104 | Terminated | Phase 2/Phase 3 | Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function | July 2002 | March 2009 |
| NCT00140140 | Terminated | Phase 1/Phase 2 | A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer | August 2005 | February 2008 |
| NCT02585388 | Terminated | Phase 2 | Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. | October 23, 2015 | May 15, 2017 |
| NCT00041470 | Terminated | Phase 1/Phase 2 | Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial | March 2001 | August 2008 |
| NCT02331251 | Terminated | Phase 1/Phase 2 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | December 2014 | January 2018 |
| NCT02213744 | Terminated | Phase 2/Phase 3 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | July 2014 | June 2017 |
| NCT04296162 | Unknown status | Phase 2 | Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) | March 1, 2019 | May 30, 2021 |
| NCT03423849 | Unknown status | Phase 2/Phase 3 | The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy | February 8, 2018 | February 8, 2020 |
| NCT04302441 | Unknown status | Phase 2 | A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy | November 10, 2016 | June 30, 2021 |
| NCT00430001 | Unknown status | Phase 3 | Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer | May 2005 | December 2008 |
| NCT04307147 | Unknown status | Phase 3 | NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy | July 3, 2018 | September 1, 2021 |
| NCT03402048 | Unknown status | Phase 3 | The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial | July 2012 | May 2021 |
| NCT03242616 | Unknown status | Phase 2 | PemVin vs Vin in Previously Treated Metastatic Breast Cancer | February 17, 2017 | December 31, 2019 |
| NCT03188159 | Unknown status | Phase 2 | Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer | July 1, 2017 | July 1, 2022 |
| NCT00168883 | Unknown status | Phase 2 | Study for Patients With Non Small Cell Lung Cancer (NSCLC) | October 2002 | December 2006 |
| NCT04745975 | Unknown status | Phase 2 | Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer | February 1, 2021 | January 2023 |
| NCT02144194 | Unknown status | Phase 2 | Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca | March 2012 | December 2017 |
| NCT01884428 | Unknown status | Phase 1 | Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma | July 2011 | December 2015 |
| NCT03656393 | Unknown status | Phase 3 | To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma | August 31, 2018 | September 30, 2020 |
| NCT01884441 | Unknown status | Phase 2 | Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients | July 2011 | July 2016 |
| NCT02607215 | Unknown status | Phase 2 | Platinum Rechallenge in Patients With Platinum-sensitive mTNBC | November 2015 | December 2022 |
| NCT03997539 | Unknown status | Phase 2 | A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | August 15, 2019 | December 30, 2021 |
| NCT02514681 | Unknown status | Phase 3 | A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer | August 1, 2015 | December 2021 |
| NCT02544243 | Unknown status | Phase 2 | Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer | September 2015 | |
| NCT04208854 | Unknown status | Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC) | April 18, 2018 | May 18, 2020 | |
| NCT02223611 | Unknown status | Phase 2 | Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection | December 2014 | December 2018 |
| NCT02579564 | Unknown status | Phase 3 | Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients | October 2016 | December 2018 |
| NCT01683175 | Unknown status | Phase 2 | Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | August 2012 | October 2020 |
| NCT01730677 | Unknown status | Phase 2 | Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab | July 2012 | December 2017 |
| NCT02733380 | Unknown status | Phase 2 | Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | May 2016 | May 2021 |
| NCT04943627 | Withdrawn | Phase 3 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | August 2, 2021 | October 22, 2021 |
| NCT01020864 | Withdrawn | Phase 2 | Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer | January 2010 | January 2012 |
| NCT03811418 | Withdrawn | Phase 3 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer | January 2019 | April 2019 |
| NCT03770299 | Withdrawn | Phase 2 | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | January 15, 2021 | March 14, 2024 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |
| NCT01137994 | Withdrawn | Phase 2 | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | October 2011 | March 2018 |
| NCT06137651 | Withdrawn | Phase 1 | Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis | December 31, 2023 | March 27, 2024 |
| NCT05711628 | Withdrawn | Phase 3 | A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma | August 10, 2023 | June 30, 2028 |